Cytokinetics (NASDAQ:CYTK) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Cytokinetics (NASDAQ:CYTK) from a sell rating to a hold rating in a research note issued to investors on Monday,Wall Street Zen reports.

A number of other analysts also recently weighed in on CYTK. Barclays boosted their target price on Cytokinetics from $95.00 to $110.00 and gave the stock an “overweight” rating in a research report on Thursday, August 13th. Truist Financial increased their price target on shares of Cytokinetics from $106.00 to $112.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Cytokinetics in a research note on Friday, September 11th. JPMorgan Chase & Co. boosted their price objective on shares of Cytokinetics from $97.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, August 13th. Finally, Royal Bank Of Canada upped their price objective on shares of Cytokinetics from $112.00 to $113.00 and gave the company an “outperform” rating in a research note on Thursday, October 8th. Eighteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Cytokinetics presently has an average rating of “Moderate Buy” and a consensus price target of $105.44.

Cytokinetics Stock Up 2.9%

NASDAQ CYTK opened at $63.43 on Monday. The stock’s 50-day simple moving average is $70.83 and its two-hundred day simple moving average is $73.27. Cytokinetics has a twelve month low of $54.30 and a twelve month high of $88.31. The company has a market capitalization of $7.89 billion, a price-to-earnings ratio of -8.79 and a beta of 0.41.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.63) by $0.13. The firm had revenue of $28.62 million for the quarter, compared to the consensus estimate of $17.59 million. The company’s revenue for the quarter was down 57.1% on a year-over-year basis. During the same period last year, the firm earned ($1.12) EPS. On average, equities analysts expect that Cytokinetics will post -5.98 earnings per share for the current fiscal year.

Insider Transactions at Cytokinetics

In other news, Director B. Parshall sold 5,000 shares of the business’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $71.48, for a total value of $357,400.00. Following the completion of the sale, the director owned 10,784 shares of the company’s stock, valued at approximately $770,840.32. The trade was a 31.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Callos sold 14,000 shares of the business’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $79.88, for a total value of $1,118,320.00. Following the completion of the sale, the executive vice president directly owned 58,555 shares of the company’s stock, valued at approximately $4,677,373.40. This trade represents a 19.30% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 191,426 shares of company stock worth $13,601,885. Company insiders own 2.60% of the company’s stock.

Institutional Trading of Cytokinetics

A number of institutional investors have recently made changes to their positions in the stock. Integrated Wealth Concepts LLC purchased a new position in shares of Cytokinetics in the second quarter worth $36,000. Rockefeller Capital Management L.P. raised its holdings in Cytokinetics by 842.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 641 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 573 shares during the last quarter. Western Wealth Management LLC purchased a new stake in Cytokinetics during the 1st quarter valued at $53,000. EverSource Wealth Advisors LLC grew its holdings in Cytokinetics by 55.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,548 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 549 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in Cytokinetics by 12.0% in the 2nd quarter. GAMMA Investing LLC now owns 2,487 shares of the biopharmaceutical company’s stock worth $212,000 after acquiring an additional 266 shares during the last quarter.

Key Headlines Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: New analyses from the Phase 3 ACACIA-HCM study showed aficamten improved exercise-capacity measures and benefited multiple responder groups in patients with non-obstructive hypertrophic cardiomyopathy. The results also supported the drug’s dose-adjustment strategy and safety profile, potentially strengthening its regulatory and commercial prospects. ACACIA-HCM additional data
• Positive Sentiment: Market coverage has renewed attention on Cytokinetics’ heart-drug pipeline, with commentary suggesting aficamten’s multi-domain benefits could improve the company’s long-term growth and valuation potential. Analysts maintain a broadly favorable view, with 18 Buy ratings, one Hold and one Sell, and an average price target of $106.06—well above recent trading levels. Analyst price target coverage
• Neutral Sentiment: Chief Executive Officer Robert Blum sold 7,500 shares for approximately $471,600 under a pre-arranged Rule 10b5-1 trading plan. He retained 278,544 shares, so the transaction represents only a 2.62% reduction in his direct holdings and is a limited signal of management sentiment. SEC Form 4 filing
• Negative Sentiment: Cytokinetics remains unprofitable, with analysts expecting a full-year loss of approximately $5.98 per share. Recent quarterly revenue also declined year over year, leaving investors focused on the timing of aficamten’s potential approval and commercialization.

Cytokinetics Company Profile

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that improve muscle function. The company applies muscle biology and molecular pharmacology to develop therapies for cardiovascular and neuromuscular diseases in which impaired muscle performance contributes to disease progression or disability.

Its lead programs include aficamten, a next-generation cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy, and other investigational compounds designed to modulate the activity of cardiac or skeletal muscle.